A biotechnology company developing a first in class Plasmacytoid Dendritic cell line, PDC*line providing unmatched advantages #immunooncology#neoantigen
📢 PDC*lung01 Phase I/II results now published in ESMO Open! authors.elsevier.com/sd/arti… of the Phase I/II clinical study evaluating the therapeutic cancer vaccine PDC*lung01 in patients with non-small cell lung cancer in ESMO Open – the journal of the @myESMO
📢
@pdc_line
at #CIMT 2025! Poster presented today at the 22nd Annual Meeting of the Association for Cancer Immunotherapy. đź“· Poster title: Humoral response in NSCLC patients treated with a plasmacytoid dendritic allogeneic cell line-based cancer vaccine with or without anti-PD1
In this interview, Eric Halioua reflects on the start, success and momentum of PDC*line Pharma, a clinical-stage biotechnology company developing allogeneic cellular immunotherapies for cancer. He also shares three top tips for start-up companies on their investment and funding journey and highlights the importance of connecting through conferences. Read now >>> hubs.ly/Q03mwxvQ0
In this interview, Eric Halioua reflects on the start, success and momentum of PDC*line Pharma, a clinical-stage biotechnology company developing allogeneic cellular immunotherapies for cancer. He also shares three top tips for start-up companies on their investment and funding journey and highlights the importance of connecting through conferences. Read now >>> hubs.ly/Q03mwxvQ0
📢 @pdc_line at #CIMT 2025! Poster presented today at the 22nd Annual Meeting of the Association for Cancer Immunotherapy. 🧬 Poster title: Humoral response in NSCLC patients treated with a plasmacytoid dendritic allogeneic cell line-based cancer vaccine with or without anti-PD1
@pdc_line is excited to be part of the 25th #BioEquityEurope Presenting Company Class of 2025!
@EricHalioua , will be attending the event next week in Bruges, Belgium
đź“… Learn more: lnkd.in/ebxFNqDm
📍 Organized by Informa Connect
We look forward to seeing you in Bruges!
Excited to be part of the 25th #BioEquityEurope Presenting Company Class of 2025 next week in Bruges, Belgium!
This year’s theme — “Can European biotech rise to the complexity of the moment?” — couldn’t be more timely.
đź“… Learn more: lnkd.in/ebxFNqDm
👉 New Video following poster presentation at the European Lung Cancer Congress 2025 #ELCC2025
We are pleased to share a video presentation by Prof. Dr. Johan Vansteenkiste, the principal investigator of our clinical trial
medimix.be/onco/?p=16201
@pdc_line Unveils New Clinical Results with PDC*lung01 at the #ELCC2025 . Poster Title: Primary analysis of safety, efficacy and immunogenicity of the therapeutic cancer vaccine PDClung01 with or without pembrolizumab in NSCLC: A multicenter phase I/II study
Exciting news! Our abstract has been accepted for a poster presentation at the European Lung Cancer Congress (ELCC) 2025. We’re proud to share new data from our ongoing clinical development program with PDC*lung01, our therapeutic cancer vaccine NSCLC.
lnkd.in/eMeKgmBn
Tomorrow’s the day! We’re excited to share that our CEO is speaking at Advanced Therapies UK 2025, where industry leaders will gather for 2 days of insightful discussions, networking, and innovation.
There’s still time to join us in London!
i.snoball.it/p/GWhk/l/5#adtherapies
I’m thrilled to be attending the J.P. Morgan Conference in San Francisco from Sunday to Wednesday evening. If you’re attending as well and would like to connect, feel free to reach out or meet me at the conference. Looking forward to dynamic discussions in this hub of innovation!
We are thrilled to be hosting an Executive Roundtable at
@WuXi_AppTec#WuXiGlobalForum during #JPM2025! I’m excited to discuss about opportunities of innovative cancer vaccines ! Learn more about the event here: lnkd.in/e36tbuAt
We are thrilled to share the primary clinical results from our Phase I/II trial of the PDC*lung01 cancer vaccine, presented at ESMO-IO 2024! PDC*lung01, combined with pembro, shows potential for meaningful clinical benefit compared to pembro alone in stage IV NSCLC patients.